Letrozol Accord

Letrozole, the active ingredient in Letrozol Accord, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the endocrine therapy of hormone‑receptor positive breast cancer in postmenopausal women, reducing estrogen production that can fuel tumor growth.

GNH USA supplies Letrozol Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, ensuring product integrity throughout the supply chain.

Letrozole is used in the endocrine therapy of hormone‑receptor positive breast cancer, acting on estrogen‑dependent tumor pathways.

- Early‑stage hormone‑receptor positive breast cancer: reduces risk of recurrence after surgery. - Metastatic hormone‑receptor positive breast cancer: slows disease progression in postmenopausal patients. - Adjuvant therapy following tamoxifen: provides continued estrogen suppression after initial treatment.

Letrozole may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Hot flashes: transient feeling of warmth and sweating. - Joint and muscle pain: arthralgia or myalgia. - Nausea: mild to moderate upset stomach. - Fatigue: persistent lack of energy. - Headache: mild to moderate cranial discomfort. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Osteoporosis and fractures: decreased bone mineral density leading to fractures. - Severe liver injury: marked elevation of transaminases or hepatitis. - Thromboembolic events: pulmonary embolism or deep vein thrombosis. - Allergic reactions (anaphylaxis): severe hypersensitivity requiring immediate medical attention. - Severe hypertension: significant increase in blood pressure that may require treatment.

When prescribing Letrozole, clinicians should consider several precautionary measures to ensure patient safety. - Assess bone health: evaluate risk of osteoporosis before initiating therapy. - Monitor liver function: perform baseline and periodic liver enzyme tests. - Check cardiovascular status: screen for hypertension or thrombotic risk. - Review concomitant medications: avoid drugs that may increase estrogen levels. - Pregnancy and lactation: contraindicated in pregnancy; advise effective contraception. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Letrozole can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce letrozole plasma levels. - Estrogen‑containing hormonal therapies (e.g., hormone replacement therapy): counteract aromatase inhibition.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): may increase bleeding risk; monitor INR. - Selective serotonin reuptake inhibitors (SSRIs): potential for altered metabolism; observe clinical response. - Tamoxifen: concurrent use may diminish therapeutic effect; consider sequencing.